J
J.A. Gilmore
Researcher at Eli Lilly and Company
Publications - 25
Citations - 2786
J.A. Gilmore is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Risperidone. The author has an hindex of 18, co-authored 25 publications receiving 2688 citations. Previous affiliations of J.A. Gilmore include Riley Hospital for Children & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
TL;DR: Hyperprolactinemia is very prevalent among women and men treated with conventional antipsychotic medications or risperidone and should be seriously considered when choosing an antipsychotics suitable for the patient.
Journal ArticleDOI
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
TL;DR: In this paper, the long-term weight change and the weightrelated health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and compared to patients treated with haloperidol.
Journal ArticleDOI
Factors Influencing Acute Weight Change in Patients With Schizophrenia Treated With Olanzapine, Haloperidol, or Risperidone
Bruce R. Basson,Bruce J. Kinon,Cindy C. Taylor,Keith A. Szymanski,J.A. Gilmore,Gary D. Tollefson +5 more
TL;DR: Clinical factors predicting weight change in patients with schizophrenia during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were identified through retrospective analyses.
Journal ArticleDOI
Olanzapine versus divalproex in the treatment of acute mania.
Mauricio Tohen,Robert W. Baker,Lori L. Altshuler,Carlos A. Zarate,Trisha Suppes,Terrence A. Ketter,Denái R. Milton,R.C. Risser,J.A. Gilmore,Alan Breier,G. Tollefson +10 more
TL;DR: The olanzapine treatment group had significantly greater mean improvement of mania ratings and a significantly greater proportion of patients achieving protocol-defined remission, compared with the divalproex treatment group.
Journal ArticleDOI
Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.
TL;DR: The regulatory mechanisms involved in prolactin secretion, the physiologic role of prolact in various pathologic states, and the etiology of hyperprolactinemia are discussed.